Strongyloidiasis Current Status with Emphasis in Diagnosis and Drug Research

Table 4

Drugs/compounds used in in vivo assays against Strongyloides spp.

Specie	Animal model	Compound	Anti-Strongyloides activity	Parasite load reduction	Dosage	Reference
S. venezuelensis	CD1 mice	2-(Butylamino) hexadecan-1-ol	Yes	56%	20 mg/kg/day for 5 days, 1 day after infection	[16]
		2-(Ethylamino) hexadecan-1-ol	No	45%
		tert-Butyl N-(1-aminododecan-2-yl) carbamate	No	21%
		tert-Butyl N-(1-aminohexadecan-2-yl) carbamate	No	50%
S. ratti	Wistar rats	Monepantel (AAD 1566)	No	0%	32 mg/kg	[27]
S. venezuelensis	Wistar rats	Piper tuberculatum extract	No	Not shown	150 mg/kg	[28]
	Wistar rats	Lippia sidoides essential oil	Yes	74.4%	150 mg/kg
S ratti	Wistar rats	Tribendimidine	Yes	98.9%	50 mg/kg 72 h after infection	[17]